New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2012
16:05 EDTPCYCPharmacyclics oral therapy ibrutinib resulted in durable responses
Pharmacyclics announced follow-up results that its investigational oral therapy ibrutinib (PCI-32765), as a single agent, resulted in durable responses for patients over 65 years of age with treatment-naive chronic lymphocytic leukemia, CLL, or small lymphocytic lymphoma, SLL, and for those with relapsed/refractory, RR, or high-risk, HR, disease.
News For PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 16, 2015
15:31 EDTPCYCPharmacyclics resumes, up 0.6% to $256.58 after HELIOS hits primary endpoint
Subscribe for More Information
15:08 EDTPCYCPharmacyclics to resume trading at 3:30 pm EDT
Subscribe for More Information
15:04 EDTPCYCPharmacyclics says committee recommends unblinding after primary endpoint met
Subscribe for More Information
14:55 EDTPCYCPharmacyclics trading halted, pending news

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use